Department of Pathology, Yale University Medical School, New Haven, CT, USA.
Biotechniques. 2012 Apr;52(4):235-45. doi: 10.2144/000113837.
MicroRNAs (miRNAs) have emerged as key regulators in the pathogenesis of cancers where they can act as either oncogenes or tumor suppressors. Most miRNA measurement methods require total RNA extracts which lack critical spatial information and present challenges for standardization. We have developed and validated a method for the quantitative analysis of miRNA expression by in situ hybridization (ISH) allowing for the direct assessment of tumor epithelial expression of miRNAs. This co-localization based approach (called qISH) utilizes DAPI and cytokeratin immunofluorescence to establish subcellular compartments in the tumor epithelia, then multiplexed with the miRNA ISH, allows for quantitative measurement of miRNA expression within these compartments. We use this approach to assess miR-21, miR-92a, miR-34a, and miR-221 expression in 473 breast cancer specimens on tissue microarrays. We found that miR-221 levels are prognostic in breast cancer illustrating the high-throughput method and confirming that miRNAs can be valuable biomarkers in cancer. Furthermore, in applying this method we found that the inverse relationship between miRNAs and proposed target proteins is difficult to discern in large population cohorts. Our method demonstrates an approach for large cohort, tissue microarray-based assessment of miRNA expression.
微小 RNA(miRNA)已成为癌症发病机制中的关键调节因子,它们可以作为癌基因或肿瘤抑制因子发挥作用。大多数 miRNA 测量方法需要总 RNA 提取物,这些提取物缺乏关键的空间信息,并且给标准化带来挑战。我们已经开发并验证了一种通过原位杂交(ISH)定量分析 miRNA 表达的方法,允许直接评估肿瘤上皮细胞中 miRNA 的表达。这种基于共定位的方法(称为 qISH)利用 DAPI 和角蛋白免疫荧光来建立肿瘤上皮细胞的亚细胞区室,然后与 miRNA ISH 多重化,允许在这些区室中定量测量 miRNA 的表达。我们使用这种方法来评估 473 个乳腺癌标本组织微阵列上的 miR-21、miR-92a、miR-34a 和 miR-221 的表达。我们发现 miR-221 水平在乳腺癌中具有预后价值,说明了高通量方法,并证实了 miRNA 可以作为癌症有价值的生物标志物。此外,在应用这种方法时,我们发现 miRNA 和拟议靶蛋白之间的反比关系在大人群队列中难以辨别。我们的方法展示了一种用于大样本量、组织微阵列 miRNA 表达评估的方法。